Change Makers in Pharma – the eyeforpharma podcast

In our CEO series, we meet with Janssen's Group Chairman to review blood cancer awareness month, discuss how where we are in the cure for cancer and look at how big pharma should help patients manage the disease journey. Ulrich Neumann, US Managing Director, eyeforpharma, speaks with Jane Griffiths, Company Group Chairman of Janssen Europe, Middle East and Africa.

While the market becomes increasingly crowded with innovator drugs, pharma is finding it harder to recoup development costs. Join our panel of experts to understand how we should build innovative, cost-effective payment models based on 21st-century definitions of value. With Tamar Thompson, Director Federal Agency Payment (Bristol-Myers Squibb), Jennifer Hinkel, Partner (McGivney Global Advisors), hosted by Ulrich Neumann, US Managing Director, eyeforpharma)

It's become widely understood that a focus on patient value has become mission critical as we witness the force of consumerization in healthcare. Join us for a wide ranging conversation on the new digital ecosystem and the type of engagement models pharma companies are currently utilizing. Ulrich speaks with Dave Rosner and Mark Lush, two experienced life sciences consultants, both principal's with Deloitte Consulting who have recently co-authored a widely cited whitepaper on the topic (Deloitte Review, Issue 18 via dupress.com).

How can pharmaceutical companies get to insights-driven customer engagement, that is the subject of today's program. We meet with one of our favorite marketing leaders over in Silicon Valley, Leilani Latimer who leads Global Marketing as Sr. Director for Zephyr Health.

Join us for this critical discussion about exploding cost in cancer care. Ahead of ASCO, we'll address some of the value frameworks and metrics, and what pharma ought to do to provide better evidence for their prices. You'll get to hear a pretty spirited debate debate between Michael Kolodziej, National Medical Director at Aetna, Steven Paulson, CEO and President at Texas Oncology and our good friend Jack Whelan at Cancer Warrior and Patient Leader.

CSL Behring's CEO in a wide-ranging conversation about value, patient focus, skyrocketing healthcare cost and the constant need to innovate.

In this conversation with pharma change maker Paulo Moreira, we'll discuss how clinical trials and drug development can become more patient friendly. Paulo is EMD Serono's Vice President and Head of Global Clinical Operations for External Innovation. He's addressing what the industry has done wrong, why a paradigm change is needed for the clinical enterprise and how external innovation and technology must be leveraged to successfully engaging patients in the future.

In this conversation with renowned industry expert Maria Whitman of ZS Associates we'll discuss the overarching trends in Oncology that are most important to consider in terms of value and market access, explore the role of pathways and new models for risk sharing. How is this playing out so far, and what is the industry response? This audiocast will offer you exclusive insights on what manufacturers need to be thinking about as they approach new product launches in Oncology.